Table 6.
Potential epigenetic drugs for the treatment of metabolic disease
| Drugs | Target gene | Diseases | References |
|---|---|---|---|
| DNMTi | |||
| hydralazine | Nrf2 | diabetic nephropathy | 378 |
| procainamide | PDX1 | diabetes | 381 |
| decitabine | PPARγ | diabetes | 382 |
| 5-aza-2’-deoxycytidine | PPARγ1 | obesity | 383 |
| 5-aza-2’-deoxycytidine | PPAR-α | NAFLD | 384 |
| 5-aza-2’-deoxycytidine | OPN, RUNX2 | diabetic osteoporosis | 385 |
| HDACi | |||
| VPA | STAT5 | T1D | 387 |
| VPA | RUNX2 | osteoporosis | 388 |
| vorinostat | OPG | diabetes | 389 |
| vorinostat | EGFR | diabetic nephropathy | 390,391 |
| SAHA | Zfp719 | obesity | 392 |
| SAHA | insulin receptor β, Akt, and FoxO1 | osteoporosis | 393 |
| Givinostat | Gata3, FOXP3, IL-6, IL-12, TNF-α | diabetes | 397 |
| Givinostat | IL-1β, IL-6 and TNF-α | diabetes | 398 |
| Givinostat | IL-6, IL-1β, TNF-α | nonalcoholic steatohepatitis | 399 |
| Dacinostat | UCP1, Ppargc1α | obesity | 400 |
| TSA | AMPK | obesity | 401 |
| Puerarin | HDAC1/HDAC3 | diabetic osteoporosis | 403 |
| HATi | |||
| Curcumin | FOXO1 | DCM | 405 |
| Curcumin | HSP-27, p38 | DN | 406 |
| C66 | CTGF, PAI-1 and FN-1 | DN | 407 |
| C646 | IRS1/2 | diabetes, obesity | 408 |
| STAC | |||
| resveratrol | SIRT1, NF-kB-p65 | cardiac oxidative stress in diabetes | 409 |
| resveratrol | SIRT1, PGC-1α | Obesity, diabetic cardiomyopathy | 410,411 |
| resveratrol | SIRT1, FOXO3a | DN | 412 |
| resveratrol | SIRT1, FOXO 1 | osteoporosis | 413 |
| HPE | SIRT1, NF-kB, p53 | DN | 414 |
| ASO | |||
| IONIS-GCGRRx | GCGR | T2D | 416 |
| Vupanorsen | ANGPTL3 | hepatic steatosis, diabetes | 417 |